Back to Search Start Over

Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors

Authors :
Gwénaël Chevé
Clémence Feneyrolles
Bénédicte Daydé-Cazals
Aurélia Spenlinhauer
Pierre Warnault
Léa Guiet
Bénédicte Fauvel
Aziz Yasri
Source :
Molecular Cancer Therapeutics. 13:2141-2148
Publication Year :
2014
Publisher :
American Association for Cancer Research (AACR), 2014.

Abstract

Receptor tyrosine kinases (RTK) are transmembrane receptors that regulate signal transduction in cells. As a member of the TAM (Tyro-3, Axl, Mer) RTK subfamily, Axl regulates key processes such as cell growth, migration, aggregation, and apoptosis through several pathways. Its overexpression/overactivation has been underlined in several conditions, especially cancers, and in both chemotherapy and targeted therapy sensitivity loss. In this review, we propose to highlight the therapeutic implication of Axl, starting with the pathways it regulates, validating its interest as a therapeutic target, and defining the tools available to develop strategies for its inhibition. We especially focus on small molecule inhibitors, their structure, inhibition profile, and development stages. Mol Cancer Ther; 13(9); 2141–8. ©2014 AACR.

Details

ISSN :
15388514 and 15357163
Volume :
13
Database :
OpenAIRE
Journal :
Molecular Cancer Therapeutics
Accession number :
edsair.doi.dedup.....7a517135961486593cc4e001e6675f4f